| Symbol | NBP |
|---|---|
| Name | I-MAB |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 555 WEST HAIYANG ROAD,55TH - 56TH FLOOR, NEW BUND CENTER, SHANGHAI, 200124, China |
| Telephone | +86 2160578000 |
| Fax | — |
| — | |
| Website | https://www.i-mabbiopharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001778016 |
| Description | I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Additional info from NASDAQ: |
New Form S-8 - NovaBridge Biosciences <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001193125-26-353173 <b>Size:</b> 1 MB
Read moreNovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
Read moreNovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
Read moreGupta Srishti 🟢 acquired 3.0M shares (1 derivative) of NovaBridge Biosciences (NBP) at $2.01 ($6.0M) Transaction Date: Jul 06, 2026 | Filing ID: 000006
Read moreNew Form 3 - NovaBridge Biosciences <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0002024011-26-000004 <b>Size:</b> 18 KB
Read moreXu Cong Claire 🟡 adjusted position in 2.5K shares (1 derivative) of NovaBridge Biosciences (NBP) at $0.89 Transaction Date: Jul 04, 2026 | Filing ID: 000005
Read moreNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
Read moreCao Sean Wuxiong 🟢 acquired 362.6K shares (2 derivative) of NovaBridge Biosciences (NBP) at $1.53 Transaction Date: Jun 22, 2026 | Filing ID: 000004
Read moreDennis Phillip Andrew 🟡 adjusted position in 4.9K shares (1 derivative) of NovaBridge Biosciences (NBP) at $0.66 Transaction Date: Jun 17, 2026 | Filing ID: 000006
Read moreNew Form 20-F/A - NovaBridge Biosciences <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001778016-26-000006 <b>Size:</b> 508 KB
Read more